|
1
|
Bennett JM, Catovsky D, Daniel MT, et al:
Proposals for the classification of the acute leukaemias
French-American-British (FAB) co-operative group. Br J Haematol.
33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bennett JM, Catovsky D, Daniel MT, et al:
Proposed revised criteria for the classification of acute myeloid
leukemia A report of the French-American-British Cooperative Group.
Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bennett JM, Catovsky D, Daniel MT, et al:
Criteria for the diagnosis of acute leukemia of megakaryocyte
lineage (M7). A report of the French-American-British Cooperative
Group. Ann Intern Med. 103:460–462. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bennett JM, Catovsky D, Daniel MT, et al:
Proposal for the recognition of minimally differentiated acute
myeloid leukaemia (AML-MO). Br J Haematol. 78:325–329. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harris NL, Jaffe ES, Diebold J, et al: The
World Health Organization classification of neoplasms of the
hematopoietic and lymphoid tissues: Report of the Clinical Advisory
Committee meeting - Airlie House, Virginia, November, 1997. Hematol
J. 1:53–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vardiman JW, Thiele J, Arber DA, et al:
The 2008 revision of the World Health Organization (WHO)
classification of myeloid neoplasms and acute leukemia: Rationale
and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yates JW, Wallace HJ Jr, Ellison RR and
Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin
(NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer
Chemother Rep. 57:485–488. 1973.PubMed/NCBI
|
|
8
|
Rai KR, Holland JF, Glidewell OJ, et al:
Treatment of acute myelocytic leukemia: A study by cancer and
leukemia group B. Blood. 58:1203–1212. 1981.PubMed/NCBI
|
|
9
|
O'Donnell MR, Abboud CN, Altman J, et al:
Acute myeloid leukemia. J Natl Compr Canc Netw. 10:984–1021.
2012.PubMed/NCBI
|
|
10
|
Swords R and Santini V: In elderly
patients with AML, which patients should be considered fit or unfit
for standard induction therapy? Hematology Am Soc Hematol Educ
Program. 2012:74–75. 2012.PubMed/NCBI
|
|
11
|
Yanada M and Naoe T: Acute myeloid
leukemia in older adults. Int J Hematol. 96:186–193. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burnett A, Wetzler M and Löwenberg B:
Therapeutic advances in acute myeloid leukemia. J Clin Oncol.
29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dombret H, Raffoux E and Gardin C: Acute
myeloid leukemia in the elderly. Semin Oncol. 35:430–438. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krug U, Büchner T, Berdel WE and
Müller-Tidow C: The treatment of elderly patients with acute
myeloid leukemia. Dtsch Arztebl Int. 108:863–870. 2011.PubMed/NCBI
|
|
15
|
Jordan CT: The leukemic stem cell. Best
Pract Res Clin Haematol. 20:13–18. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
She M, Niu X, Chen X, et al: Resistance of
leukemic stem-like cells in AML cell line KG1a to natural killer
cell-mediated cytotoxicity. Cancer Lett. 318:173–179. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ardekani AM, Akhondi MM and Sadeghi MR:
Application of genomic and proteomic technologies to early
detection of cancer. Arch Iran Med. 11:427–434. 2008.PubMed/NCBI
|
|
18
|
Biomarkers Definitions Working Group, .
Biomarkers and surrogate endpoints: Preferred definitions and
conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisterer W, Bechter O, Hilbe W, et al:
CD44 isoforms are differentially regulated in plasma cell
dyscrasias and CD44v9 represents a new independent prognostic
parameter in multiple myeloma. Leuk Res. 25:1051–1057. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niitsu N and Iijima K: High serum soluble
CD44 is correlated with a poor outcome of aggressive non-Hodgkin's
lymphoma. Leuk Res. 26:241–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krause DS, Spitzer TR and Stowell CP: The
concentration of CD44 is increased in hematopoietic stem cell
grafts of patients with acute myeloid leukemia, plasma cell
myeloma, and non-Hodgkin's lymphoma. Arch Pathol Lab Med.
134:1033–1038. 2010.PubMed/NCBI
|
|
22
|
Mi Y and Bian S: Acute
leukemiaStandardization of Hematologic Disease Diagnosis and the
Therapeutic Effect. Zhinan Z and Ti S: 1. 3rd. Science Press;
Beijing, China: pp. 131–134. 2007
|
|
23
|
Wang Z, Zheng T, Wu Q and Wang J, Wu C and
Wang J: Immunohistochemical analysis of the mTOR pathway in
intrahepatic cholangiocarcinoma. Neoplasma. 59:137–141. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu J, Liu YL, Piao SL, et al: Expression
patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in
non-small-cell lung cancer. Lung Cancer. 77:593–599. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao L, Hu X, Zhang J, Liang P and Zhang Y:
CD44 U(+) CD324(–) expression and prognosis in gastric cancer
patients. J Surg Oncol. 110:727–733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Opitz I, Soltermann A, Abaecherli M, et
al: PTEN expression is a strong predictor of survival in
mesothelioma patients. Eur J Cardiothorac Surg. 33:502–506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tapia O, Riquelme I, Leal P, et al: The
PI3K/AKT/mTOR pathway is activated in gastric cancer with potential
prognostic and predictive significance. Virchows Arch. 465:25–33.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sebban C, Browman GP, Lepage E and Fière
D: Prognostic value of early response to chemotherapy assessed by
the day 15 bone marrow aspiration in adult acute lymphoblastic
leukemia: A prospective analysis of 437 cases and its application
for designing induction chemotherapy trials. Leuk Res. 19:861–868.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cortes J, Fayad L, O'Brien S, Keating M
and Kantarjian H: Persistence of peripheral blood and bone marrow
blasts during remission induction in adult acute lymphoblastic
leukemia confers a poor prognosis depending on treatment intensity.
Clin Cancer Res. 5:2491–2497. 1999.PubMed/NCBI
|
|
30
|
Fitzgerald KA, Bowie AG, Skeffington BS
and O'Neill LA: Ras, protein kinase C zeta, and I kappa B kinases 1
and 2 are downstream effectors of CD44 during the activation of
NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. J
Immunol. 164:2053–2063. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bourguignon LY, Zhu H, Shao L, Zhu D and
Chen YW: Rho-kinase (ROK) promotes CD44v(3,8–10)-ankyrin
interaction and tumor cell migration in metastatic breast cancer
cells. Cell Motil Cytoskeleton. 43:269–287. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin YH and Yang-Yen HF: The
osteopontin-CD44 survival signal involves activation of the
phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem.
276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dick JE, Bhatia M, Gan O, Kapp U and Wang
JC: Assay of human stem cells by repopulation of NOD/SCID mice.
Stem Cells. 15:199–207. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krause DS and Van Etten RA: Right on
target: Eradicating leukemic stem cells. Trends Mol Med.
13:470–481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oelschlaegel U, Bornhauser M, Boxberger S,
et al: Kinetics of CXCR-4 and adhesion molecule expression during
autologous stem cell mobilisation with G-CSF plus AMD3100 in
patients with multiple myeloma. Ann Hematol. 86:569–573. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Rhenen A, Moshaver B, Kelder A, et al:
Aberrant marker expression patterns on the CD34+CD38- stem cell
compartment in acute myeloid leukemia allows to distinguish the
malignant from the normal stem cell compartment both at diagnosis
and in remission. Leukemia. 21:1700–1707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Buzzai M and Licht JD: New molecular
concepts and targets in acute myeloid leukemia. Curr Opin Hematol.
15:82–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Spaeth EL, Labaff AM, Toole BP, et al:
Mesenchymal CD44 expression contributes to the acquisition of an
activated fibroblast phenotype via TWIST activation in the tumor
microenvironment. Cancer Res. 73:5347–5359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lane SW, Scadden DT and Gilliland DG: The
leukemic stem cell niche: Current concepts and therapeutic
opportunities. Blood. 114:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stiles B, Groszer M, Wang S, Jiao J and Wu
H: PTENless means more. Dev Biol. 273:175–184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dahia PL, Aguiar RC, Alberta J, et al:
PTEN is inversely correlated with the cell survival factor Akt/PKB
and is inactivated via multiple mechanisms in haematological
malignancies. Hum Mol Genet. 8:185–193. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheong JW, Eom JI, Maeng HY, et al:
Phosphatase and tensin homologue phosphorylation in the C-terminal
regulatory domain is frequently observed in acute myeloid leukaemia
and associated with poor clinical outcome. Br J Haematol.
122:454–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Squarize CH, Castilho RM, Abrahao AC, et
al: PTEN deficiency contributes to the development and progression
of head and neck cancer. Neoplasia. 15:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
da Costa AA, D'Almeida Costa F, Ribeiro
AR, et al: Low PTEN expression is associated with worse overall
survival in head and neck squamous cell carcinoma patients treated
with chemotherapy and cetuximab. Int J Clin Oncol. May
27–2014.(Epub ahead of print).
|
|
46
|
Hede K: PTEN takes center stage in cancer
stem cell research, works as tumor suppressor. J Natl Cancer Inst.
98:808–809. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He XC, Yin T, Grindley JC, et al:
PTEN-deficient intestinal stem cells initiate intestinal polyposis.
Nat Genet. 39:189–198. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yilmaz OH, Valdez R, Theisen BK, et al:
Pten dependence distinguishes haematopoietic stem cells from
leukaemia-initiating cells. Nature. 441:475–482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tesio M, Oser GM, Baccelli I, et al: Pten
loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J
Exp Med. 210:2337–2349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chu TH, Chan HH, Kuo HM, et al: Celecoxib
suppresses hepatoma stemness and progression by up-regulating PTEN.
Oncotarget. 5:1475–1490. 2014.PubMed/NCBI
|
|
51
|
Salminen A and Kaarniranta K:
Insulin/IGF-1 paradox of aging: Regulation via AKT/IKK/NF-kappaB
signaling. Cell Signal. 22:573–577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dubrovska A, Kim S, Salamone RJ, et al:
The role of PTEN/Akt/PI3K signaling in the maintenance and
viability of prostate cancer stem-like cell populations. In: Proc
Natl Acad Sci USA. 106. pp. 268–273. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lee CH, Jeon YT, Kim SH and Song YS:
NF-kappaB as a potential molecular target for cancer therapy.
Biofactors. 29:19–35. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Breccia M and Alimena G: NF-κB as a
potential therapeutic target in myelodysplastic syndromes and acute
myeloid leukemia. Expert Opin Ther Targets. 14:1157–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kamieńska E, Ociepa T, Wysocki M, et al:
Activation of NF-κB in leukemic cells in response to initial
prednisone therapy in children with acute lymphoblastic leukaemia:
Relation to other prognostic factors. Pol J Pathol. 62:5–11.
2011.PubMed/NCBI
|
|
57
|
Lounnas N, Frelin C, Gonthier N, et al:
NF-kappaB inhibition triggers death of imatinib-sensitive and
imatinib-resistant chronic myeloid leukemia cells including T315I
Bcr-Abl mutants. Int J Cancer. 125:308–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
